Biogen shares rise as FDA nears ruling on controversial Alzheimer's drug

The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's (BIIB.O) aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data.